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The progesterone receptor (PR) is an important prognostic marker
in breast cancer (Horwitz et al, 1975). Oestrogen receptor
(ER)-positive breast tumours that also contain PR are considered
‘good prognosis’ tumours and are likely to respond to endocrine
therapies (Horwitz et al, 1978). In contrast, absence of PR often
characterizes ‘poor prognosis’ tumours (ER + PR–) and resistance
to endocrine therapy (McGuire et al, 1991).
Similar to other members of the steroid receptor superfamily,
PR is divided into structural domains (A–E) (Figure 1), the
functions of which are widely documented (Tsai and O’malley,
1994). Two different PR isoforms, PR-A and PR-B, that are
encoded by mRNAs transcribed from the same gene under the
control of two different promoters (Kastner et al, 1990), have been
identified in both normal and neoplastic tissues (Figure 1). The
presence of several exon-deleted PR variant mRNAs in both
normal and neoplastic breast samples has recently been reported
(Leygue et al, 1996a; Richer et al, 1998; Yeates et al, 1998).
Amongst them was a variant mRNA deleted in exon 6 (D6-PR
mRNA) that, if translated, would encode a PR-A-like and/or a
PR-B-like protein containing a truncated E domain. This variant,
missing the hormone binding domain and one of the transacti-
vating domains (AF-2) of the wild-type (WT) PR protein, has been
shown to act in-vitro as a dominant-negative transcriptional
inhibitor of PR-A and PR-B isoforms (Richer et al, 1998). Because
expression of analogous exon-deleted or truncated variants has
been associated with tumour progression in the case of ER variant
mRNAs (for review see Murphy et al, 1997), it was of interest to
determine whether D6-PR variant expression was also modified
during tumorigenesis. In this study, we investigated D6-PR variant
expression by reverse transcription polymerase chain reaction
(RT-PCR) in ten normal reduction mammoplasties samples, nine
breast tumours with high PR levels (considered ‘good prognostic’
tumours) and eight breast tumours with low PR levels (considered
‘poor prognosis’ tumours).
MATERIALS AND METHODS
Human breast tissues
Human breast specimens (27 cases) were from the Manitoba
Breast Tumor Bank (Winnipeg, Manitoba, Canada). The
processing of specimens collected in the Manitoba Breast Tumor
Bank has already been described (Hiller et al, 1996). Briefly, each
specimen was rapidly frozen as soon as possible after surgical
removal. A portion of the frozen tissue block was processed to
create a paraffin-embedded tissue block matched and orientated
relative to the remaining frozen block. These paraffin blocks
provide high quality histologic sections, which are used for
pathologic interpretation and assessment and are mirror images of
the frozen sections used for RNA extractions. For each case,
tumour and normal tissues were histologically characterized by
observation of paraffin sections. The presence of normal ducts and
lobules as well as the absence of any proliferative lesion were
confirmed in all ten normal reduction mammoplasties specimens.
The 17 primary invasive ductal breast carcinomas were associated
with high ER levels ranging from 105 to 386 fmol mg–1 protein
(mean = 190.7 fmol mg–1 protein, standard deviation (s.d.) =
58.49), as determined by ligand binding assay. Within this group,
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Summary The progesterone receptor (PR) is an important prognostic marker in breast cancer as well as a marker of responsiveness to
endocrine therapies. The presence of several exon-deleted PR variant mRNAs in both normal and neoplastic breast samples has recently
been reported. Amongst them, a variant mRNA deleted in exon 6 (D6-PR mRNA) that if translated would encode a truncated PR-like protein
missing the hormone binding domain and one of the transactivating domains of the wild-type PR protein. In order to determine whether
changes in D6-PR variant expression could occur during tumorigenesis, its expression was investigated by reverse transcription and
polymerase chain reaction in ten normal reduction mammoplasty samples, nine breast tumours with high PR levels (> 100 fmol mg–1 protein)
and eight breast tumours with low PR levels (< 15 fmol mg–1 protein), as determined by ligand binding assay. The relative expression of
D6-PR to wild-type PR mRNA was lower (P < 0.01) in normal than in all tumour breast samples. Moreover, a trend to lower (P < 0.1) relative
D6-PR expression was observed in high PR tumours, compared to low PR tumours. These data suggest that increased expression of D6-PR
occurs during tumorigenesis.
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Correspondence to: E Leyguenine tumours had a high PR level (PR > 100 fmol mg–1 protein,
mean = 156.4 fmol mg–1 protein, s.d. = 28.4) and eight had a low
PR level (PR < 15 fmol mg–1 protein, mean = 8.6 fmol mg–1
protein, s.d. = 4.6), as determined by ligand binding assay. The
ages of patients associated with the tumour samples ranged from
37 to 91 (mean: 70 years old, s.d.: 14.4 years). For reduction
mammoplasties, women were younger, with ages ranging from 19
to 41 years old (mean: 31.3 years old, s.d.: 8.3 years). Total RNA
was extracted from frozen tissue and reverse transcribed in a final
volume of 15 ml as previously described (Leygue et al, 1996b).
PCR and identification of PCR products
The primers used consisted of D6U primer (5¢-CTCT-
CATTCAGTATTCTTGG-3¢; sense; located in PR exon 5;
2989–23008) and D6L primer (5¢-TGGGTTTGACTTCGTAGC-
3¢; antisense; located in PR exon 7; 3262–3245). The nucleotide
positions correspond to published sequences of the human PR
cDNA (Kastner et al, 1990). PCR amplifications were performed
and PCR products analysed as previously described, with minor
modifications (Leygue et al, 1996b). Briefly, 1 ml of reverse tran-
scription mixture was amplified in a final volume of 10 ml, in the
presence of 10 nmol–1 [a-32P] dCTP, 4 ng ml–1 of each primer and
0.3 unit of Taq DNA polymerase. Each PCR consisted of 40 cycles
(30 s at 60°C and 30 s at 94°C). As positive controls, aliquots of
plasmid DNA containing previously (Leygue et al, 1996a)
subcloned WT-PR (WT cont) or exon 6-deleted PR (D6 cont)
sequences were amplified in parallel. PCR products were then
separated on 6% polyacrylamide gels containing 7 M urea (PAGE).
Following electrophoresis, the gels were dried and autoradio-
graphed. The PCR product corresponding in size to D6-PR was
subcloned and sequenced as previously described (Leygue et al,
1996b).
Quantification and statistical analysis
The approach used to evaluate the exon-deleted variant mRNA
expression relative to WT mRNA has been previously validated
for exon-deleted ER variant mRNAs (Daffada et al, 1994; Leygue
et al, 1996b). PCR co-amplification of WT and exon-deleted
variant generates two bands whose ratio is constant with varying
cycle number and is independent of initial input cDNA. This assay
provides a semi-quantitative RT-PCR in which the internal control
is the WT mRNA co-amplified and in which relative expression of
variant mRNA can be determined for individual samples. Bands
corresponding to D6-PR and WT mRNAs were excised from the
gel and corresponding signals were subsequently measured after
addition of 5 ml scintillant (ICN Pharmaceuticals, Inc., Irvine, CA,
USA) by counting. The D6-PR signal was expressed as a
percentage of the WT-PR signal. For each sample, three indepen-
dent assays were performed and the mean determined. The
statistical significance of differences in the relative levels of
expression of D6-PR mRNAs was determined using the
Mann–Whitney rank-sum test (two-sided).
RESULTS
Detection of D6-PR in all normal and tumour breast
tissues
Total RNA from ten normal breast tissues and 17 breast tumour spec-
imens was analysed by RT-PCR as described in Material and Methods
using primers depicted in Figure 1. These primers were designed to
allow the co-amplification of D6-PR and WT-PR mRNAs. Among
the 17 tumours studied, nine had a high PR level (> 100 fmol mg–1
protein) and eight had a low PR level (< 15 fmol mg–1 protein), as
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Figure 1 Schematic representation of PR-B protein, PR-B and PR-A
cDNAs and primers used to co-amplify WT-PR and D6-PR variant cDNAs.
PR cDNAs contain eight different exons coding for a protein divided into
structural and functional domains (A–E). A/B region of the receptor contains
two transactivating domains (AF3 and AF1). The C region contains the DNA
binding domain whereas region E, which is involved in hormone binding,
contains another transactivating domain (AF2). ATG-B and ATG-A are the
translational start sites of PR-B and PR-A proteins respectively. TGA, stop
codon. D6U and D6L primers allow co-amplification of 274 bp and 143 bp
fragments corresponding to WT-PR and D6-PR mRNAs, respectively
Figure 2 Detection of exon 6-deleted PR variant mRNA in all human breast
samples. Total RNA extracted from normal (N1–3), high PR tumour
(HPR1–3) and low PR tumour (LPR1–3) breast tissue samples was reverse
transcribed and PCR-amplified as described in Material and Methods, using
D6U and D6L primers. Radioactive PCR products were separated on a 6%
acrylamide gel and visualized by autoradiography. Bands that migrated at
274 bp and 143 bp were identified as corresponding to WT-PR and exon 6-
deleted PR variant mRNAs, respectively. Plasmids containing either WT-PR
(WT cont) or exon 6-deleted PR (D6 cont) sequences were used as positive
control. M: molecular weight marker (j´ 174 HaeIII digest, Gibco BRL, Grand
Island, NY, USA). C: no cDNA added during the PCR reaction
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that corresponded in size to that expected for WT-PR and D6-PR PCR
products were obtained. Figure 2 presents a typical autoradiograph
after one night’s exposure. It should be noted that a longer exposure or
addition of intensifying screens allowed the detection of D6-PR in
both lanes N3 and LPR3 (data not shown). One should also note the
presence, in samples where WT-PR signal is high (such as in lane N2,
Figure 2), of some minor PCR products, that are not reproducibly
obtained and therefore were not further characterized. The PCR
product corresponding in size to D6-PR and reproducibly obtained
was subcloned and subsequently sequenced. Sequence analysis
showed the expected perfect junction between exon 5 and exon
7 (data not shown).
Comparison of D6-PR variant expression in normal and
tumour tissues
The D6-PR variant mRNA expression relative to WT-PR was then
evaluated in each sample. It has been previously demonstrated that
the co-amplification of WT and exon-deleted variant transcripts
led to the synthesis of two PCR products. Further, the ratio of the
signals obtained from these two products could be used to compare
relative exon-deleted variant expression within samples (Daffada
et al, 1994; Leygue et al, 1996b). The signal corresponding to
D6-PR was expressed as a percentage of the WT-PR signal and the
mean of three different assays calculated (Figure 3). The level of
exon 6-deleted variant mRNA relative to the WT-PR mRNA was
found to be significantly (P < 0.05) lower in normal (median =
4.8%) than in neoplastic breast tissues having either high PR or
low PR (median = 9.19% and median = 25.13% respectively). The
significance became higher (P < 0.01) when the tumour subgroups
were considered together (median = 13.86%). Moreover, even
though the difference did not achieve statistical significance
(0.1 < P < 0.05), D6-PR relative expression appeared lower in
tumours with high PR levels (median = 9.19%) than in tumours
with low PR levels (median = 25.13%).
DISCUSSION
This study shows that the relative expression of D6-PR variant
mRNA is altered between normal breast tissue and breast cancer
tissue samples. The expression of D6-PR variant mRNA relative
to WT-PR mRNA was investigated using a previously described
semi-quantitative RT-PCR assay (Daffada et al, 1994; Leygue
et al, 1996b). This assay allows the determination of the expres-
sion of PR variant mRNA relative to WT-PR mRNA using the
very small amount of starting material provided by histopatho-
logically well-characterized regions within human breast tissue.
It is important to establish whether or not this differential
expression of D6-PR variant is maintained at the protein level.
Anti-PR antibodies available to date (such as hPRa-7; Clarke et al,
1987), while able to recognize the predicted PR variant proteins,
cannot provide any information on the unique primary sequence of
the recognized molecule (Yeates et al, 1998). We are in the process
of developing an antibody, raised against the predicted 12 specific
C-terminal amino acids of the D6-PR protein (Leygue et al, 1996a)
that could be used for the specific immunochemical detection of
D6-PR variant protein within paraffin-embedded breast tissue
sections or by Western blotting.
The recombinant D6-PR protein, has recently been shown to
bind constitutively the progesterone receptor element (PRE) DNA
consensus sequence and to exhibit dominant-negative activity
on PR-A-and PR-B-induced transcription (Richer et al, 1998).
Interestingly, a naturally occurring ER variant mRNA deleted in
exon 7 and encoding an analogous truncated molecule lacking
the hormone binding domain of the WT-ER can also act as a
dominant-negative regulator of WT-ER, at least under some
circumstances (Wang and Miksicek, 1991; Fuqua et al, 1992).
Relative levels of some of the ER variants were found to be
increased during tumour progression. Exon 7-deleted variant
mRNA level was shown to be higher in ER + PR – versus ER + PR
+ tumours (Fuqua et al, 1992). Exon 5-deleted ER variant mRNA
expression was found higher in ER – PR + versus ER + PR +
tumours (Fuqua et al, 1991) and was decreased in normal versus
tumour breast tissues (Leygue et al, 1996b). It has thus been
speculated that expression of these ER variants may be altered
during breast tumorigenesis and progression and may have a role
in progression from hormone dependence to independence in
breast cancer (Murphy et al, 1997). This aspect of tumour progres-
sion consists of altered oestrogen signalling, the acquisition of
resistance to the cytostatic effects of the anti-oestrogen tamoxifen
and subsequently in the failure to respond to agents such
progestins and probably antiprogestins (RU 486) (Horwitz et al,
1995). The apparent lower relative expression of D6-PR in normal
breast samples compared to tumour tissues, as well as in high PR
tumours compared to low PR tumours, is therefore of interest,
since normal tissue, high PR tumours and low PR tumours may
represent steps in tumour progression which correlate with
increasing relative D6-PR expression. In order to clarify such
issues, larger numbers of samples require screening for D6-PR
expression.
The measurement of PR is an important tool in clinical decision-
making with respect to prognosis and treatment of human breast
cancer. Furthermore, the level of PR expression provides impor-
tant clinical information as shown by Clark et al (1983). As the use
of enzyme-linked immunosorbent assays (ELISA) and immuno-
histochemical assays for PR detection increases, it is likely that
variant PR expression will interfere with these assays. Such
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Figure 3 Comparison of D6-PR relative expression between normal and
tumour samples. Total RNA extracted from ten normal breast samples (´),
nine tumours with high PR (l, HPR) and eight tumours with low PR (l l, LPR)
was reverse transcribed and PCR-amplified as described in Material and
Methods, using D6U and D6L primers. D6-PR corresponding signal was
measured as described in Material and Methods and expressed as a
percentage of wild-type PR corresponding signal. For each sample, the
mean of three different experiments is indicated. Bars: medians
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HPR LPR HPR + LPRcapability of variant forms of receptor to possibly interfere with
immunohistochemical detection of the WT molecule has recently
been demonstrated for ER (Huang et al, 1997 and unpublished
data).
In conclusion, we show in this study that exon 6-deleted PR
variant mRNA relative expression is increased during breast
tumorigenesis. We speculate that PR variants may have a role in
tumorigenesis and/or be a marker of breast cancer progression, as
already suggested for ER variants.
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